Tuesday, June 17, 2008
Mixed Results for Experimental Alzheimer’s Antibody
The highly anticipated results of an experimental Alzheimer’s treatment from Wyeth and Elan look OK, but not great. Yet even mediocre results were enough to boost shares of the companies. In afternoon trading, Elan shares were up $1.70, or 6%, to $28.81, and Wyeth shares rose $1.97, or 5%, to $45.05. The treatment, an antibody [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment